

Interface and Formulary Update - Issue 34

February 2025

Key messages from February 2025 TAG meeting (ratified by Medicines Optimisation Programme Board)

Commissioning Review Cytisine / Cytisinicline for smoking cessation	<ul style="list-style-type: none"> ADVICE - GP prescribable after consultant/specialist recommendation where the specialist is a smoking cessation adviser (level 2 or 3) in line with similar treatments
Commissioning Review Inclisiran for primary hypercholesterolaemia or mixed dyslipidaemia	<ul style="list-style-type: none"> Reminder this is classified as ADVICE. No special training prior to initiation Pathway - LipidManagement PPMO Lipid_01022026.pdf Commissioning summary - InclisiranBulletin.pdf Netformulary entry - Norfolk and Waveney Formulary
Commissioning Review Micronised Progesterone for threatened miscarriage in those with confirmed intrauterine pregnancy with vaginal bleeding and history of previous miscarriage, or history of recurrent miscarriage	<ul style="list-style-type: none"> ADVICE - Hospital will stabilise patient, initiate treatment and give 2 weeks supply, then primary care will be asked to provide the remainder of the 16-week course Ensure timely communication from the trusts to GP practices regarding the continuation of prescriptions. To recommend that primary care prescribe 4-weekly to reduce risk of waste If added to repeat, please ensure end date recorded.

Formulary and Guidance Updates

Formulary Amendments

- Diavic** – brand added to liraglutide following discontinuation of Victoza
- Zinc sulfate 125mg eff tabs, 220mg caps** – entry updated to **GREEN** for diagnosed deficiency and **Self-Care** for all other indications such as insufficiency, prevention or maintenance
- Levobunolol eye drops** - preservative free preparation discontinued 2024. Alternatives can be found on Netformulary
- Lymphoedema items** - removed from TAG spreadsheet pending review
- Naltrexone (opioid dependence)** - changed from **yellow** to **red specialist only**. Entry will still include details on the specific specialist services who supply this treatment to patients. This change aims to simplify the classifications and ensure clarity in prescribing responsibilities.
- Hypnotics and Parkinson's Disease** – suggested updates as part of Chapter 4 Netformulary review

Traffic Light Classification updates

As part of traffic light classification review, the **following classifications and related drugs have been removed from TAG spreadsheet:**

- GREEN**
- NON FORMULARY**
- YELLOW**
- OTC**
- DISCONTINUED**

Drugs will still be listed on Netformulary, so information will not be lost. Aim to focus the TAG spreadsheet on more complex treatments rather than standard primary care drugs.

Guidance Updates

- eRD document - **Role of Champions** – published on KNoW to support ongoing work - [eRD_RoleOfChampions_PPMO_PracticeSupport.pdf](#)
- GP Response Form: Request to prescribe in Primary Care DECLINED** - Updated version published on KNoW - [GPResponseForm_PPMO_PracticeSupport.docx](#)

Shared Care Updates

[Use of Donepezil, Galantamine, Rivastigmine and Memantine](#) in the treatment of Dementia

Amendments include:

- Further year added to review date

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

Hospital	TA697 – July 2021, updated January 2025 Andexanet alfa (Ondexxya®) for reversing anticoagulation from apixaban or rivaroxaban
	TA1027 – January 2025 Tebentafusp (Kimtrak®) for treating advanced uveal melanoma
	TA1030 – January 2025 Durvalumab (Imfinzi®) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
	TA1031 – January 2025 Vamorolone (Agamree®) or treating Duchenne muscular dystrophy in people 4 years and over
	TA1034 – January 2025 Anhydrous sodium thiosulfate (Pedmarqsi®) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours
	TA1035 – January 2025 Vadadustat (Vafseo®) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease
BLACK	TA1028 – January 2025 Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)
	TA1029 – January 2025 Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)
	TA1032 – January 2025 Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)

Useful Information

Next TAG meeting	Wednesday 5th March 2025
Deadline for agenda submissions	Tuesday 25th February 2025
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – Medicines Optimisation Home Page	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- **Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates**
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net